We are currently working on a major website expansion project with exciting new features, information and resources. Please enjoy this beta version of our website and visiting us again soon!
To improve health by providing access to the most clinically relevant PET and SPECT radiopharmaceuticals to assist physicians in the diagnosis of life threatening disease We are committed to: the long-term success of our employees and shareholders, providing new diagnostic options to healthcare professionals, and the welfare of our patients.
ISOLOGIC has taken a leadership position in supplying the Canadian nuclear medicine community with clinically relevant radiopharmaceuticals. Our proven success in developing and commercializing innovative imaging agents provides strong evidence of our willingness to bring forward breakthrough radiopharmaceuticals to market. With state-of-the-art facilities across Central Canada, and strategic alliances with world-renowned university research hospitals and dedicated expert resources, ISOLOGIC is ready to expand its offering to include the next generation of PET and SPECT compounds and provide nuclear medicine centers with the most significant tools to improve patient care.